Ovid Therapeutics : Corporate Presentation

®

Ovid Therapeutics

Corporate Overview

(NASDAQ: OVID)

©2023 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED	JANUARY 2023

Disclaimers and forward-looking statements

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the timing and development of Ovid's product candidate pipeline and achievement of expected near- and long-term milestones; the potential therapeutic benefits of

Ovid's current or future product candidates and pipeline programs; the reporting of preclinical data for OV329; the reporting of data for Phase 1 study in healthy volunteers for OV329; the potential use of OV329 to treat rare and treatment-resistant forms of epilepsy and seizures; the clinical and regulatory development of OV329, including the anticipated timing of clinical trials of OV329 and other KCC2 compounds in the Company's library; the likelihood that data for OV329 will support future development and therapeutic potential; the potential development of OV350; the suitability of the Company's library of novel, direct KCC2 transporter activators for a range of formulations and administrations that would make it possible to pursue both chronic and acute epilepsies; the timing for filing of the Company's IND applications; the potential benefits of

Gensaic's proprietary phage-derived platform; the timing for the completion of Takeda's two pivotal Phase 3 trials evaluating soticlestat for Lennox-Gastaut and Dravet syndromes; the success of Takeda's trials in soticlestat; the duration of the Company's cash runway, and the expectation that it will support the advancement of the Company's pipeline; Ovid's business development intentions; the success of any licensing or partnering opportunities, the success, timing, ability to attract and maintain strategic collaborations; the clinical and regulatory development and potential commercialization of soticlestat, OV350, or any of Ovid's other current or future product candidates and pipeline programs and market opportunities You can identify forward-looking statements because they contain words such as "will," "plan", "believes", intends," "anticipates," "strives," "pursue," "design," "advance," "target," "seek," "expects," and "potential" and similar expressions (as well as other words or expressions referencing future events,

conditions or circumstances).

Forward-looking statements are based on Ovid's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid's ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its technology or its business strategy, risks related to Ovid's ability to identify business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions and risks to Ovid's or any of its partners' abilities to meet anticipated deadlines and milestones presented by the ongoing COVID-19 pandemic. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption "Risk Factors" in Ovid's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 8, 2022, and in future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

The trademarks included in this presentation are the property of the owners thereof and are used for reference purposes only.

©2023 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED		2

				Focused epilepsy pipeline
				with significant unmet need & large
				addressable market
				Substantial milestones & royalties
		due from Takeda surrounding potential
	®
				regulatory approval & commercial sales
				of soticlestat
Transforming the lives of	Veteran team
individuals with epilepsies
& rare neurological	with track record of value creation
diseases	& transformative transactions
				Cash runway into 2025
				& disciplined approach to
				business development
							3
				©2023 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

Epilepsy market is a promising opportunity

Significant patient need

30 - 40%

of individuals have seizures not controlled with anti- seizure medicines1

De-risked development

Validated & emerging targets cause neuronal hyperexcitability

Small molecules that can cross the blood-brain barrier

Large addressable market

65 million

people living with epilepsy worldwide3

47%

of patients take 5 medicines on average, demonstrating need for unique, well tolerated anti- seizure mechanisms2

Predictive, clinically- translatable seizure models

Hard endpoints (seizures) and biomarkers

3 million

people living with epilepsy in US4

1. Huron Primary Research (11/2019-12/2019)
2. Terman SW, Aubert CE, Hill CE, et al. Polypharmacy in patients with epilepsy: a nationally representative cross-sectional study. Epilepsy Behav. 2020;111:107261.
3. Epilepsy fast facts. Centers for Disease Contr Easl and Prevention. Updated September 30, 2020. Accessed July 12, 2022.https://www.cdc.gov/epilepsy/about/fast-facts.htm.
4. CDC Epilepsy data:https://www.cdc.gov/epilepsy/data/index.html
5. Global Data Report, Epilepsy: Global Drug Forecast and Market Analysis to 2030 - Forecast Update

©2023 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

>$8B

global market opportunity5

4

Advancing epilepsy pipeline						Small molecule
					Genetic target
SMALL MOLECULE	INDICATION/TARGET	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	ANTICIPATED
MILESTONES
OUT-LICENSED TO	Dravet syndrome					•	Phase 3 data from 2
SOTICLESTAT						registrational trials
						Filing marketing
CH24H inhibitor						•
	Lennox-Gastaut syndrome						authorization submissions
							in Takeda's FY 2024
OV329	Tuberous Sclerosis Complex, infantile					•	Phase 1 target
GABA-aminotransferase						engagement & safety
spasms and focal seizures
inhibitor						findings - H1 2024
IN-LICENSED FROM
OV350	Resistant epilepsies and other					•	Anticipated IND in 2024
neuro-pathologies
KCC2 transporter activator
NUCLEIC ACID	INDICATION / TARGET	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3		MILESTONE
OV882	Angelman syndrome
Collaborator: UCONN
OV815	KAND - KIF1A associated-neurological
Collaborator: Columbia Univ.	disorders

OV825 HNRNPH2

Collaborator: Columbia Univ.

UNDISCLOSED PROGRAMS WITH COLUMBIA UNIVERSITY & RESEARCH

COLLABORATION WITH GENSAIC

STRATEGIC BUSINESS DEVELOPMENT ACTIVITIES FOCUSED ON COMPLEMENTING OUR GENETIC TARGETS & AUGMENTING CLINICAL STAGE ASSETS

©2023 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED		5